Eli Lilly said Tuesday that it expects earnings per share next year in the range of $6.70 to $6.80, with overall revenue between of $23.6 billion and $24.1 billion, driven by growth from key products such as Taltz and Trulicity. Analysts predict earnings in 2020 of $6.63 per share, with sales of around $23.5 billion for the year.

Chief financial officer Josh Smiley remarked "we expect 2020 to be a year of strong operating and financial performance…characterised by revenue growth for our key medicines both in the US and in international markets." The company indicated that there is the possibility for two regulatory approvals and up to three new launches next year.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.